

Uroplakin II antibody IVD, 7/13:104

Biocare Medical's uroplakin II mouse monoclonal antibody (IVD) is now available. Studies have shown UP II mRNA to be expressed in bladder cancer tissues and the peripheral blood of patients with primary and metastatic urothelial carcinoma.

Pathologists have used uroplakin III [AU1] to establish urothelial origin of the bladder; however, use of UP III is limited owing to its poor sensitivity. UP II was found to have 79 percent (44/56) sensitivity for bladder urothelial carcinoma compared with 34 percent (19/56) for UP III [AU1] in a joint study conducted by Biocare Medical, Mercy Health System, and Indiana University School of Medicine.

With the exception of bladder and ureter, uroplakin II [BC21] was found to be 100 percent specific when evaluated in various normal and neoplastic tissues. Uroplakin II [BC21] is a highly specific antibody that may be useful in identifying tumors of urothelial origin. Patent pending.

Biocare Medical, 800-799-9499